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Abstract: Type 2 diabetes (T2D) imposes a substantial disease burden, predominantly from 
cardiovascular disease (CVD), which accounts for .50% of deaths in this population and leads 
to a 12-year reduction in the life expectancy of a 60-year-old male patient with T2D and CVD 
compared with the general population. The results from mandatory cardiovascular outcome 
trials (CVOTs) are therefore of great interest in the field. The Academy for Cardiovascular Risk, 
Outcomes and Safety Studies in Type 2 Diabetes meeting program aims to bring together experts 
from several associated disciplines to provide fair and balanced resources for those involved in 
the management of patients with T2D. This publication represents the opinions of the faculty on 
the key learnings from the meeting held in Vienna in the spring of 2017. In particular, we detail 
how data from the EMPA-REG OUTCOME® [cardiovascular outcomes trial of empagliflozin] 
and Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results 
(LEADER®) (liraglutide) CVOTs can be practically interpreted across clinical specialities. 
It is hoped that this translation of CVOT data will achieve a dual treatment paradigm for the 
management of both raised glucose levels and CV risk in patients with T2D.
Keywords: type 2 diabetes, cardiovascular disease, CVOT, SGLT2 inhibitors, GLP-1 agonists, 
DPP-4 inhibitors
Introduction
For every 11 adults worldwide, one person is living with diabetes, equating to 
415 million people (projected to increase to 642 million by 2040).1 Around 90% of 
these individuals have type 2 diabetes (T2D).1 T2D represents a substantial disease 
burden to each patient, often involving multiple comorbidities.2 Cardiovascular disease 
(CVD) is chief among these, accounting for .50% of deaths in patients with T2D. 
The life expectancy of a 60-year-old male patient with T2D and CVD is reduced by 
12 years compared with the general population.1–3 There are multiple therapeutic agents 
now available or in the pipeline for the treatment of T2D (Figure 1), and establishing 
their cardiovascular (CV) safety has become a key factor in the approval process, with 
cardiovascular outcomes trials (CVOTs) now being mandatory for all new agents.
No increased CV risk was observed in the three CVOTs that had been 
reported at the time of this meeting and statistical superiority was demonstrated 
in two of them:4–7 EMPA-REG OUTCOME® [cardiovascular outcomes trial of 
empagliflozin], which investigated the sodium/glucose cotransporter 2 (SGLT2) 
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inhibitor empagliflozin, and Liraglutide Effect and Action 
in Diabetes: Evaluation of Cardiovascular Outcome Results 
(LEADER®), which investigated the glucagon-like peptide 1 
(GLP-1) receptor agonist liraglutide. Significant protection 
for certain CV outcomes was reported in these two CVOTs 
(Box 1 and Table 1), enabling physicians to both control 
glucose levels and lower CV risk with a single agent. In 
addition, the SUSTAIN™-6 non-inferiority study of sema-
glutide reported some positive results, although further 
study will need to be performed to demonstrate superiority. 
In addition, semaglutide is not currently licenced; therefore, 
the results were not discussed in any depth at this particular 
meeting. Since the meeting, the results of the Canagliflozin 
Cardiovascular Assessment Study of the SGLT2 inhibitor 
canagliflozin have been published, which also showed a 
statistically significant benefit for 3-point major adverse CV 
events.8 A further publication is in preparation following a 
subsequent meeting to discuss these results. Overall, the 
CVOT results have the potential to enable a profound shift 
in clinical practices across the T2D-related specialities, such 
as endocrinology, cardiology, and nephrology.
The Academy for Cardiovascular Risk, Outcomes and 
Safety Studies in Type 2 Diabetes program was initiated 
with the aim of providing education and resources for health 
care professionals managing patients with T2D within the 
Figure 1 Completed and ongoing cardiovascular outcome trials in type 2 diabetes.
Note: Copyright ©2017. Dove Medical Press. Reproduced from schernthaner G, Jarvis s, Lotan C, Prázný M, Wanner C, Wascher TC. Advances in the management of 
cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and safety studies in Type 2 Diabetes. Ther Clin Risk 
Manag. 2017;13:69–79.3
Abbreviations: Cv, cardiovascular; CvOT, cardiovascular outcome trial; DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1; sGLT2, sodium/glucose 
cotransporter 2; CANVAS, Canagliflozin Cardiovascular Assessment Study; CANVAS-R, Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects with 
T2DM; CARMeLiNA®, Cardiovascular safety and Renal Microvascular Outcome study with Linagliptin; CAROLiNA®, Cardiovascular Outcome study of Linagliptin versus 
Glimepiride in Patients with Type 2 Diabetes; CREDENCE, Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic 
Nephropathy; DECLARE-TIMI, Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events; ELIXA, Evaluation of Lixisenatide in Acute 
Coronary Syndrome; EXAMINE, Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care; EXSCEL, The EXenatide Study of Cardiovascular Event 
Lowering; OMNeON™ [randomized, double-blind, placebo-controlled, multicenter study to assess cardiovascular outcomes following treatment]; ReWiND, Researching 
Cardiovascular events with a Weekly incretin in Diabetes; sAvOR-TiMi, saxagliptin Assessment of vascular Outcomes Recorded in Patients with Diabetes Mellitus–
Thrombolysis in Myocardial infarction; TeCOs, Trial evaluating Cardiovascular Outcomes with sitagliptin; LeADeR®, Liraglutide effect and Action in Diabetes: evaluation 
of Cardiovascular Outcome Results; eMPA-ReG OUTCOMe® [cardiovascular outcomes trial of empagliflozin]; SUSTAIN, Trial to Evaluate Cardiovascular and Other 
Long-term Outcomes With Semaglutide in Subjects with Type 2 Diabetes; T2DM, type 2 diabetes mellitus; 3P-MACE, 3-point major adverse CV events (CV death, 
nonfatal myocardial infarction or nonfatal stroke); 4P-MACE, 4-point major adverse CV events (CV death, nonfatal myocardial infarction, nonfatal stroke or unstable angina 
requiring hospitalization).
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Box 1 Significant CV outcomes in CVOTs
eMPA-ReG OUTCOMe® (empagliflozin): 
Death from Cv causes:
3.7% vs 5.9% in the placebo group; HR, 0.62; 95% Ci 0.49–0.77;  
p,0.001
Hospitalization for HF:
2.7% vs 4.1%; HR, 0.62; 95% Ci 0.49–0.77; p,0.001
Death from any cause:
5.7% vs 8.3%; HR, 0.68; 95% Ci 0.57–0.82; p,0.001
LeADeR® (liraglutide):
Death from Cv causes:
4.7% vs 6.0% in the placebo group; HR, 0.78%; 95% Ci 0.66–0.93; 
p=0.007
Death from any cause:
8.2% vs 9.6%; HR, 0.85; 95% Ci 0.74–0.97; p=0.02
Abbreviations: CI, confidence interval; CV, cardiovascular; CVOT, cardiovascular 
outcomes trial; HF, heart failure; HR, hazard ratio; eMPA-ReG OUTCOMe®, 
[cardiovascular outcomes trial of empagliflozin]; LEADER®, Liraglutide effect and 
Action in Diabetes: evaluation of Cardiovascular Outcome Results.
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Central and East European region. A range of tools and 
information has been developed in collaboration with an 
expert steering committee, including primary and specialist 
care experts from cardiology, endocrinology, diabetology, 
and nephrology, to provide fair and balanced resources that 
are aligned to the needs and challenges facing health care 
practitioners (HCPs) involved in the management of patients 
with T2D (available at Academy for Cardiovascular Risks, 
Outcomes and Safety Studies in Type 2 Diabetes (T2D), 
2017; https://www.across-t2d.com). The steering commit-
tee also provides guidance on the interpretation and com-
munication of clinical data and, where applicable, provides 
guidance on regional/national adaptation of the international 
recommendations. A series of biannual Scientific Exchange 
Meetings across Latin America, Europe, and Asia has also 
allowed direct peer-to-peer communication and education, 
with the most recent being held in Vienna in the spring of 
2017 (March 22–24). The specified educational aims of the 
Vienna meeting were:
•	 review areas of outstanding unmet medical needs in the 
management of patients with T2D;
•	 consider the impact of the published CVOTs on clinical 
practice and treatment recommendations;
•	 discuss and address safety topics of the SGLT2 inhibitor 
class and interpret the CVOT data for clinical practice 
through case discussions.
This publication represents the opinions of the faculty on 
the key learnings from the meeting, detailing how the discus-
sions of CVOT data have led to insights into the practical 
application of these data across clinical specialities for the 
treatment of both raised glucose levels and CV risk in patients 
with T2D within the region.
T2D is a chronic and complex condition requiring a duality 
of treatment: CV benefits together with glucose-lowering 
benefits in microvascular outcomes. It is more imperative that 
the benefits of collaboration and awareness between speci-
alities are recognized, leading to more effective treatment 
for the patient across multiple T2D morbidities.
CV morbidity and mortality remain the biggest burden of 
the disease, although advances in glucose-lowering therapies 
have decreased microvascular complications over the past 
decade.9–15 Furthermore, we have come to understand that 
renal protection should also be an integral part of the newly 
emerging treatment paradigm, being intricately linked to 
the effects of T2D. Renal and cardiac factors are closely 
linked, and acute or chronic disorders in one frequently 
induce dysfunction in the other. Elderly patients with 
chronic kidney disease are also more likely to die of heart 
disease than to advance to end-stage renal disease and 
dialysis.16,17
The renal sub-analyses of the EMPA-REG OUTCOME 
study indicated that, in addition to the overall study data 
showing no adverse renal effects from empagliflozin, there 
were also significant renoprotective outcomes for patients 
with both new onset and established renal disease.6,18
In this landscape of T2D comorbidities, the potential for 
combining glucose lowering with protection against CVD, 
as well as new and worsening nephropathy and proteinuria, 
is welcome for both physicians and patients. Indeed, the 
ability to treat on more than one disease front was seen by 
delegates as a novel addition to the treatment paradigm, 
and communication of this paradigm, both directly to col-
leagues and through guidelines, was a key message from the 
meeting discussions.
The positive CVOT results set 
the scene for an update to the 
treatment paradigm
The empagliflozin CVOT EMPA-REG OUTCOME was a pio-
neer study within the CVOT landscape, being among the first 
published, and the first to demonstrate cardioprotection. As 
such, the positive CV outcomes reported in this trial have set 
the scene for the new treatment approach of combining glucose 
lowering with protection against CVD.19 Direct comparison 
cannot be made between EMPA-REG OUTCOME and the 
liraglutide CVOT LEADER, given that they were not head-
to-head studies and had some variation between their study 
populations and certain outcome measures. Nevertheless, as 
both these CVOTs reported positive CV outcomes, it is useful 
to consider the main results of each (Table 1 and Box 1).
Table 1 Positive CvOT studies in T2D -percentage reduction in key outcomes
3P-MACE CV death All-cause 
mortality
Hospitalization 
for HF
Doubling of 
serum creatinine
eMPA-ReG 
OUTCOMe®
14%* 38%* 32%* 35%* 44%*
LeADeR® 13%* 22%* 15%* 13% 12%
Note: *Statistically significant.
Abbreviations: CV, cardiovascular; 3P-MACE, 3-point major adverse CV events (CV death, nonfatal myocardial infarction or nonfatal stroke); CVOT, cardiovascular 
outcome trial; HF, heart failure; eMPA-ReG OUTCOMe®, [cardiovascular outcomes trial of empagliflozin]; LEADER®, Liraglutide effect and Action in Diabetes: evaluation of 
Cardiovascular Outcome Results; T2D, type 2 diabetes.
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In patients with T2D and established CVD, the addition of 
empagliflozin to standard of care reduced CV mortality and 
hospitalization for heart failure (HF), and improved overall 
survival compared with placebo. The overall safety profile of 
empagliflozin was consistent with that observed in previous 
clinical trials and the current label information.6,19,20
In patients with T2D and established CVD or at high CV 
risk, the addition of liraglutide to standard of care reduced CV 
mortality and improved overall survival. The most common 
adverse events leading to discontinuation of liraglutide were 
gastrointestinal events.5
From the physicians’ perspective, empagliflozin and lira-
glutide currently represent two agents with the most robust 
available data for use in the treatment pathway as an add-on 
therapy to metformin for patients with T2D and established 
CVD. This has particularly been recognized for empagli-
flozin, with both US and European Union (EU) regulators 
approving changes to the product label that emphasize the 
importance of the CV benefits of the drug. The indication 
information in the US label now contains the statement “Jard-
iance is a SGLT2 inhibitor indicated: As an adjunct to diet and 
exercise to improve glycaemic control in adults with T2D. 
To reduce the risk of CV death in adult patients with T2D 
and established CVD”.21,22 The EU label update reinforces 
the concept that both improvement of glycemic control and 
reduction of CV morbidity and mortality are an integral part 
of the treatment of T2D. Across Europe and globally, inter-
national and local guidelines have been updated to include 
recommendations based on CVOT data, most notably data 
from EMPA-REG OUTCOME.23–28 This is also true for the 
European Society of Cardiology (ESC) guidelines, further 
enhancing the perception among physicians that these agents 
are now firmly positioned in the treatment pathway.29–31
Empagliflozin safety profile
A discussion point of particular significance at the meeting 
was the question of safety of some SGLT2 inhibitors. 
Concerns that have been raised in the past include risks of 
ketoacidosis, osteoporosis, urinary tract infections, hypogly-
cemic episodes, urinary and genital tract infections, kidney 
disease, and amputations.6,18,32,33 However, data from EMPA-
REG OUTCOME have shown that empagliflozin was not 
associated with a serious adverse event signal compared with 
placebo.4,19,34 For example, the study found no increased risk 
of adverse renal outcomes or bone fracture, despite the con-
cerns that have been raised with other SGLT2 inhibitors.4,19,34 
Reassuringly, genital infections, which are easily self-treated 
by over-the-counter medications, were the only adverse 
events to show a significant increase over placebo.19
Initial concerns raised by nephrologists regarding the kid-
ney targeting mode of action (MoA) of empagliflozin, as an 
SGLT2 inhibitor, have therefore largely been assuaged, and 
nephrologists now have a positive opinion of empagliflozin 
based on the renal sub-analyses of EMPA-REG OUTCOME, 
which showed that patients who received empagliflozin in 
addition to standard of care had a significantly lower risk of 
progression of kidney disease, either as new or worsening 
nephropathy.6,18
The safety data in EMPA-REG OUTCOME also demon-
strate that, conceptually, it may not be necessary to under-
stand the intricacies of the MoA of empagliflozin – as yet 
not fully understood – given that there is now reassurance 
from safety data, combined with proven efficacy.3,20 After 
all, metformin was, and is, still prescribed almost universally 
without such an understanding.
Is there a class effect?
Guidelines such as those authored by the American Diabetes 
Association or ESC recognize the importance of recom-
mending only those molecules that have demonstrated CV 
protection in a CVOT, and not extending this recommenda-
tion automatically to other molecules in the same class.29,30,35 
At the time of writing this manuscript, empagliflozin and 
liraglutide were the only approved antidiabetic agents to have 
demonstrated CV protection in CVOTs. Differentiating data 
on safety and side effects demonstrate that an overall class 
effect of SGLT2 inhibitors has not yet been shown. Although 
molecules of dapagliflozin and canagliflozin are similar to 
those of empagliflozin, small differences in the molecular 
structure can potentially lead to critical differences in func-
tion. For example, the molecular differences beween the 
hormones testosterone and estradiol are substantially smaller 
than the differences between empagliflozin molecule and the 
other two members of the class (National Center for Biotech-
nology Information PubChem Compound Database: com-
pound identity [CID] =6013; CID =5757; CID =11949646; 
CID =9887712; CID =24812758). Furthermore, CVOT 
results have been mixed between different GLP-1 receptor 
agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors, which 
supports the notion that data from one drug cannot necessarily 
be extrapolated to drugs in the same class.5,36–39 Although the 
SGLT2 inhibitors may seem to be similar to one another in 
terms of efficacy and safety,40–44 a CVOT is needed to define 
the CV effects of the other members.
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The value of SGLT2 inhibitors in 
patients with lower CV risk
It is noteworthy that uptake of the SGLT2 inhibitor class to 
date has been lower than might have been expected consid-
ering the excellent efficacy and reassuring safety data for 
empaglifozin. One of the explanations put forward for why 
the use of SGLT2 inhibitors as second-line therapy after 
metformin is much less compared with DPP-4 inhibitors is 
the assumption that glucose-lowering drugs cannot change 
CV morbidity/mortality when used in patients with early T2D 
who present with a low CV/renal risk. DPP-4 inhibitors have 
been in use for almost 10 years and are very well-tolerated, so 
any shift toward the use of SGLT2 inhibitors (in particular, 
to empagliflozin) is more often seen in patients with estab-
lished CVD. Recently, three observational studies (THIN, 
NORDIC, and CVD-REAL) reported analyses of the effect of 
SGLT2 inhibitors in patients with T2D and low CV risk.41–43 
A similar trend to EMPA-REG OUTCOME was shown in 
THIN and CVD-REAL, suggesting that all-cause mortality 
and hospitalization for HF may be statistically lower when 
SGLT2 inhibitors were initiated compared with other glucose-
lowering drugs, even in patients with low CV risk. However, 
as the event rates in these studies were very low (,1.0%) 
and the 95% confidence intervals were wide, these data can 
only be considered as relatively low level. In the NORDIC 
study, the use of new glucose-lowering drugs (the SGLT2 
inhibitor dapagliflozin and DPP-4 inhibitors) was compared 
with the administration of insulin, which, in Sweden, is used 
comparatively early in the disease. Mortality was significantly 
lower when dapagliflozin or DPP-4 inhibitors were used com-
pared with insulin, and a direct comparison of the SGLT2 
inhibitor versus the DPP-4 inhibitors showed superiority of 
the former for all endpoints analyzed.44 The observational 
design and the lack of randomization cannot totally exclude 
a prescription bias, that is, preferred use of SGLT2 inhibitors 
in patients with a lower risk, as this was not documented in 
the comparison. Despite these limitations and the differences 
in the background treatment and predominant use of different 
SGLT2 inhibitors in the US compared with Europe, a similar 
risk reduction was seen across all six countries involved in 
CVD-REAL. These well-performed observational studies, 
which trend in the same direction, add to the emerging view 
that SGLT2 inhibitors are the drug of choice in the majority 
of patients with T2D and either established CVD or CV risk 
factors. However, only prospective, well-performed CVOTs 
such as EMPA-REG OUTCOME can offer robust evidence 
of significant CV benefits.
HF and subclinical HF are among the earliest CV com-
plications seen during the follow-up of patients with T2D 
who had not exhibited evidence of CVD at baseline,45 which 
may explain the positive CV outcomes with the early use 
of SGLT2 inhibitors that was observed in the real-world 
studies. Furthermore, as HF is associated with the highest 
mortality rates in patients with T2D,20 the potential benefits of 
SGLT2 inhibitors in reducing the risk of HF could explain the 
reduction in mortality. It is important, therefore, to emphasize 
to prescribers the potential benefit to patients at all stages 
of T2D. To this end, continued education and support for 
both primary and specialist HCPs are desirable. Although 
endocrinologists and cardiologists both currently prescribe 
empagliflozin, they often operate quite separately, whereas 
increased collaboration may lead to improved outcomes by 
treating the whole disease and by increasing awareness of 
when cross-referring would be beneficial for the patient.46
Maximizing efficacy
Although numerous international and regional guidelines 
have been updated to include the prescribing of antidiabetic 
agents based on CVOT data, a majority recommend a free 
choice of agents after metformin. There is, however, a per-
ceived need for more specific direction toward those agents 
that may be most suitable for particular patients. A simple-
to-use intuitive format, rather than an exhaustive narrative, 
would be of the greatest use – what may be referred to per-
haps as “smart guidelines”. Indeed, the Canadian, Swiss, and 
Russian guidelines include a concise algorithm/table format, 
and discussion at the meeting showed that these were well-
received by faculty and delegates alike. A clear pathway, 
with guidance on the place of each agent within it, would be 
a valuable support tool for endocrinologists, cardiologists, 
and primary care physicians (PCPs) alike.
Perceived barriers to prescribing SGLT2 inhibitors 
include concerns about publicized adverse events, reimburse-
ment issues, discrepancies in guidelines, lack of regular local 
updates (eg, reluctance to update the guidelines further until 
there is more evidence on class effects for SGLT2 inhibi-
tors), and, significantly, inertia. In the workshop sessions in 
particular, where smaller group sizes allowed more in-depth 
discussion, an unwillingness among attending physicians’ 
peers to change their habitual practice of prescribing well-
used or cheaper drugs, such as metformin or sulfonylureas 
(SUs), was discussed. In addition, hospital payers resist 
reimbursing the newer agents until SUs have been tried. 
To overcome these barriers, it was felt that a program of 
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education was needed, ideally led by local physician advo-
cates. By sharing safety and efficacy data from the CVOT 
studies that show the dual benefits of antidiabetic agents that 
can both lower glucose levels and reduce CV risk in patients 
with T2D, it is hoped that physicians’ inertia to changing 
prescription habits will be overcome, leading to increased 
pressure on payers to release reimbursement.
Although the prime impetus for change may come from 
education, collaboration can also be a great influencer. 
T2D does not exist in isolation from other morbidities, and 
it is clear that the complexity of the disease means that it is 
often encountered by specialists from outside the diabetes 
therapy area, such as those in the fields of cardiology and 
nephrology. During the course of any one person’s jour-
ney with T2D, a series of specialists can be encountered, 
including PCPs, diabetologists, internalists, cardiologists, 
nephrologists, ophthalmologists, diabetes nurses/educators, 
and even orthopedists and surgeons. It is important that all 
physicians who deal frequently with patients with T2D are in 
possession of the most suitable therapies for each individual 
patient. As the complexity of T2D can often lead to patients 
suffering from multiple morbidities, it is not desirable for 
each specialism to focus on only one aspect (such as dia-
betologists on HbA1c, cardiologists on blood pressure, or 
nephrologists on estimated glomerular filtration rate). Instead, 
cross-collaboration may help to treat the whole disease more 
effectively, in addition to increasing awareness of when it 
is appropriate to refer a patient from one specialism to the 
other. By working together, and by considering the new dual 
paradigm explored at this meeting, the concerns of both dia-
betologists and cardiologists can be addressed using a single 
antidiabetic agent.
We should note that the discussions that took place at 
this meeting were of an informal, qualititative nature. The 
limitations of such a structure mean that quantitative analyses 
were not appropriate; so this report represents the opinions 
of the faculty, rather than a formal recommendation.
Conclusion
It is apparent that T2D is a complex disease, requiring a 
multifactorial approach to achieve the best outcomes. With 
more than half of all patients with T2D still dying from CVD, 
it is clear that the whole disease needs to be treated: both 
CV risk and glucose levels. Risk factors such as unhealthy 
lifestyles (notably poor-quality diet, physical inactivity, 
and smoking) and hypertension need to be addressed, and a 
simpler therapy regimen instigated that can provide treatment 
suitable for all patients, for example, patients with hepatic 
or renal insufficiency or HF. So far, empagliflozin is the 
only drug that has emerged with proven efficacy and safety 
across all these aspects. In addition, empagliflozin is the first 
antidiabetic agent to be supported by health authorities and 
official guidelines for the dual use of glucose lowering and 
reducing CV risk. In the future, HCPs working with patients 
with T2D will need to consider how best to work together 
to maximize the benefits seen from this important addition 
to the pharmaceutical armamentarium.
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